Medicare Enrolled
Dr. Houtan Golzari, M.D.
Internal Medicine · Newburyport, MA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Golzari from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Golzari?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Golzari
Dr. Houtan Golzari is an internal medicine specialist in Newburyport, MA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Golzari performed 750 Medicare services across 433 unique beneficiaries.
Between the years covered by Open Payments, Dr. Golzari received a total of $16,439 from 65 pharmaceutical and/or device companies across 1015 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Golzari is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 35% volume in MA
$16,439 industry payments
Medicare Practice Summary
Medicare Utilization ↗750
Medicare services
Top 35% in MA for internal medicine
433
Unique beneficiaries
$76
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~39 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
339 | $62 | $300 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
125 | $83 | $375 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
98 | $63 | $375 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
43 | $64 | $325 |
| Home health agency supervision, complex multidisciplinary care Supervision by a physician or allowed practitioner for a patient receiving Medicare-covered services from a participating home health agency. This involves complex and multidisciplinary care modalities, with the patient not present during the supervision. |
39 | $82 | $293 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
29 | $139 | $450 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
21 | $132 | $352 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
15 | $279 | $352 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
15 | $131 | $400 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
14 | $42 | $250 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
12 | $12 | $72 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$16,439
Total received (2018-2024)
Avg $2,348/year across 7 years
Top 9% in MA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
65
Companies
1,015
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,762 (95.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$677 (4.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,784
2023
$3,018
2022
$2,615
2021
$2,995
2020
$1,127
2019
$2,720
2018
$2,181
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$449
Corium, LLC
$166
Lilly USA, LLC
$131
Novo Nordisk Inc
$108
Boehringer Ingelheim Pharmaceuticals, Inc.
$95
Otsuka America Pharmaceutical, Inc.
$86
Amgen Inc.
$80
E.R. Squibb & Sons, L.L.C.
$77
AstraZeneca Pharmaceuticals LP
$73
Abbott Laboratories
$66
Sumitomo Pharma America, Inc.
$60
Tolmar, Inc.
$47
PFIZER INC.
$45
Lundbeck LLC
$43
Novartis Pharmaceuticals Corporation
$40
Seqirus USA Inc
$40
Antares Pharma, Inc.
$32
Kyowa Kirin, Inc.
$29
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$22
Janssen Pharmaceuticals, Inc
$20
Medtronic, Inc.
$16
Axsome Therapeutics, Inc.
$16
Acella Pharmaceuticals, LLC
$15
Phathom Pharmaceuticals, Inc.
$14
GlaxoSmithKline, LLC.
$13
Top 3 companies account for 41.8% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$1,772
Lilly USA, LLC
$1,257
AstraZeneca Pharmaceuticals LP
$1,251
GlaxoSmithKline, LLC.
$1,061
Janssen Pharmaceuticals, Inc
$858
Boehringer Ingelheim Pharmaceuticals, Inc.
$845
Novo Nordisk Inc
$782
PFIZER INC.
$755
Astellas Pharma US Inc
$743
Takeda Pharmaceuticals U.S.A., Inc.
$721
Allergan Inc.
$592
Novartis Pharmaceuticals Corporation
$569
Amgen Inc.
$547
AbbVie Inc.
$519
Corium, LLC
$503
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$356
E.R. Squibb & Sons, L.L.C.
$303
Lundbeck LLC
$299
Sunovion Pharmaceuticals Inc.
$285
Sumitomo Pharma America, Inc.
$239
AbbVie, Inc.
$177
Tolmar, Inc.
$175
Otsuka America Pharmaceutical, Inc.
$168
Biohaven Pharmaceutical Holding Company Ltd.
$100
Antares Pharma, Inc.
$98
Mylan Specialty L.P.
$97
SANOFI-AVENTIS U.S. LLC
$91
Abbott Laboratories
$83
ITI, Inc.
$81
IDORSIA PHARMACEUTICALS US INC
$70
Kowa Pharmaceuticals America, Inc.
$69
Collegium Pharmaceutical, Inc.
$60
Biohaven Pharmaceuticals, Inc.
$56
Merck Sharp & Dohme LLC
$52
Esperion Therapeutics, Inc.
$51
Medtronic, Inc.
$47
Merck Sharp & Dohme Corporation
$43
Supernus Pharmaceuticals, Inc.
$41
Seqirus USA Inc
$40
Teva Pharmaceuticals USA, Inc.
$39
Lucid Diagnostics Inc.
$39
Allergan, Inc.
$39
Daiichi Sankyo Inc.
$38
Genentech USA, Inc.
$37
Kyowa Kirin, Inc.
$29
Zimmer Biomet Holdings, Inc.
$27
BioCryst US Sales Co., LLC
$25
Purdue Pharma L.P.
$23
Boston Scientific Corporation
$22
Insmed, Inc.
$21
Shield Therapeutics Inc
$21
Bayer HealthCare Pharmaceuticals Inc.
$21
Avanir Pharmaceuticals, Inc.
$21
Eisai Inc.
$18
Endo Pharmaceuticals Inc.
$17
Ironshore Pharmaceuticals Inc.
$17
Horizon Therapeutics plc
$17
JAZZ PHARMACEUTICALS INC.
$17
Axsome Therapeutics, Inc.
$16
Acella Pharmaceuticals, LLC
$15
Neos Therapeutics, LP
$15
Phathom Pharmaceuticals, Inc.
$14
Circassia Pharmaceuticals Inc
$13
Acerus Pharmaceuticals Corporation
$12
Scilex Pharmaceuticals Inc.
$11
Top 3 companies account for 26.0% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · AIMOVIG · AJOVY · ANORO · ANORO ELLIPTA · APRISO · ARALAST · AVEED · AZSTARYS · Adzenys XR-ODT · Aimovig · Amitiza · Arikayce · Auvelity · Azstarys · BASAGLAR · BELSOMRA · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BRINTELLIX · BROVANA · CAPLYTA · CHANTIX · CLOSUREFAST · COSENTYX · CREON · ClosureFast · Creon · Crysvita · Dayvigo · ELIQUIS · EMGALITY · ENTRESTO · EUCRISA · EVENITY · FARXIGA · FASENRA · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · Fluad · Flucelvax · GARDASIL 9 · GEMTESA · Gel-One Cross-linked Hyaluronate · INJECTAFER · JANUVIA · JARDIANCE · JATENZO · JYNARQUE · Jornay PM 20mg capsules (Bottle of 100) · KRYSTEXXA · Kerendia · LEQVIO · LINZESS · LOKELMA · LYRICA · Livalo · MOUNJARO · MYRBETRIQ · Morphabond ER · Myrbetriq · NETSPOT · NEXLETOL · NOCDURNA · NORTHERA · NP Thyroid 60 · NUEDEXTA · NURTEC ODT · Natesto · OFEV · ORLADEYO · Otezla · Ozempic · PAXLOVID · PNEUMOVAX 23 · PRADAXA · PREMARIN · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · QELBREE · QULIPTA · QUVIVIQ · RELISTOR ORAL · REXULTI · RYBELSUS · Repatha · Rybelsus · SOLIQUA 100/33 · SPIRIVA RESPIMAT · SPRAVATO · STIOLTO · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · SYMPROIC · SYNJARDY · SYNTHROID · Saxenda · Seglentis · Superion Indirect Decompression System · Synthroid · TOUJEO · TOVIAZ · TRADJENTA · TRELEGY ELLIPTA · TRINTELLIX · TRULANCE · TRULICITY · TUDORZA PRESSAIR · Trintellix · UBRELVY · Uloric · VENASEAL · VIBERZI · VOQUEZNA · VRAYLAR · VYEPTI · VYNDAQEL · VYVANSE · Veozah · Vyvanse · XARELTO · XIFAXAN · XTAMPZA · XYOSTED · Xofluza · Yupelri · ZEPBOUND · ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 9% for internal medicine in MA.
Geographic Context
Internal medicine physicians within 10 mi
552
Per 100K population
68.4
County median income
$99,431
Nearest hospital
ANNA JAQUES HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Golzari is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 9% of MA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Golzari experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Golzari performed 339 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Golzari receive payments from pharmaceutical companies?
Yes. Dr. Golzari received a total of $16,439 from 65 companies across 1,015 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Golzari's costs compare to other internal medicine physicians in Newburyport?
Dr. Golzari's average Medicare payment per service is $76. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Golzari) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Newburyport
Browse internal medicine physicians in Newburyport ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in MA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in MA
Which MA internal medicine physicians receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Lilly USA, LLC Payments to Doctors
See all physicians who received payments from Lilly USA, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology